AzurRx BioPharma Inc.
www.azurrx.com
Latest From AzurRx BioPharma Inc.
Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.
Pipeline Watch: Phase III Starts With VX-445, Reproxalap And AVXS-101
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Progress With Esaxerenone, Lusutrombopag
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Starts With Gilteritinib, Lumateperone, Pro 140
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Company Information
- Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Gastrointestinal
- Infectious & Viral Diseases
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- AzurRx BioPharma Inc.
- Senior Management
-
James Sapirstein, CEO
Maged Shenouda, CFO
Daniel Dupret, PhD, CSO - Contact Info
-
AzurRx BioPharma Inc.
Phone: (646) 699-7855
760 Parkside Ave., Ste. 270
Brooklyn, NY 11226
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice